New Rosacea Treatments

One of the hottest areas of interest online for rosacea sufferers is new rosacea treatments. From the industry heavyweights like Galderma, Allergan, Bayer, Valeant and Stiefel to little companies like MooGoo there is a lot of interest in the up and coming rosacea treatments. See below for the latest information about what is just over the horizon.

Recent Rosacea Blog Posts

DFD-29 set to be approved on Nov 4 2024

News today that Journey Medical Corporation is looking forward to having their Oracea competitor, still known as DFD-29, approved by the FDA before the end of the year. Having accepted the New Drug Application, the FDA is now in the final stages of approving this new 40mg minocycline that is showing promise as a treatment […]

Continue Reading

DFD-29 on it’s way, now has an NDA

Journey Medical’s modified released 40mg minocycline (still code named DFD-29) has published positive Phase 3 Clinical Trial data and is now sitting waiting on a New Drug Application. The company press release touts the combination treatment for both the inflammatory lesions and the redness of rosacea. By comparison, Oracea, the competing product that DFD-29 claims […]

Continue Reading

Everything new and emerging for rosacea

Dermatology and Therapy has published a lengthy article detailing emerging therapies that are on the horizon for rosacea sufferers. It may seem like new and promising treatments for rosacea are few and far between. In recent years we have seen Mirvaso, Rhofade and Soolantra approved and make their way to rosacea sufferers. More recently Zilxi […]

Continue Reading

DFD-29 from Journey Medical may best out Oracea

Journey Medical Corporation are readying to release their Phase 3 clinical trial data for DFD-29, their delayed release 40mg minocycline treatment for rosacea. Targeted as a competitor to Galderma’s successful doxycycline based Oracea, the yet to be named DFD-29 is expected to release clinical data that will demonstrate superior treatment results. According to Journey Medical’s […]

Continue Reading

Hovione – Topical Minocycline Gel starts Phase 3 testing

Promoted as being safer than systemic antibiotics, a 3% formulation of topical minocycline gel has passed Phase 2 clinical trials and is readying to commence Phase 3 trials. The owners of the product, currently named HY-01 – Hovione are promoting their in-development topical as more moisturising than other comparable topicals, and less likely to induce […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.